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Abstract
Background: Pulmonary fibrosis may result from abnormal alveolar wound repair after injury. Hepatocyte growth factor
(HGF) improves alveolar epithelial wound repair in the lung. Stem cells were shown to play a major role in lung injury, repair
and fibrosis. We studied the presence, origin and antifibrotic properties of HGF-expressing stem cells in usual interstitial
pneumonia.
Methods: Immunohistochemistry was performed in lung tissue sections and primary alveolar epithelial cells obtained from
patients with usual interstitial pneumonia (UIP, n = 7). Bone marrow derived stromal cells (BMSC) from adult male rats were
transfected with HGF, instilled intratracheally into bleomycin injured rat lungs and analyzed 7 and 14 days later.
Results: In UIP, HGF was expressed in specific cells mainly located in fibrotic areas close to the hyperplastic alveolar
epithelium. HGF-positive cells showed strong co-staining for the mesenchymal stem cell markers CD44, CD29, CD105 and
CD90, indicating stem cell origin. HGF-positive cells also co-stained for CXCR4 (HGF+/CXCR4+) indicating that they originate
from the bone marrow. The stem cell characteristics were confirmed in HGF secreting cells isolated from UIP lung biopsies.
In vivo experiments showed that HGF-expressing BMSC attenuated bleomycin induced pulmonary fibrosis in the rat,
indicating a beneficial role of bone marrow derived, HGF secreting stem cells in lung fibrosis.
Conclusions: HGF-positive stem cells are present in human fibrotic lung tissue (UIP) and originate from the bone marrow.
Since HGF-transfected BMSC reduce bleomycin induced lung fibrosis in the bleomycin lung injury and fibrosis model, we
assume that HGF-expressing, bone-marrow derived stem cells in UIP have antifibrotic properties.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with
a complex pathophysiology and very limited therapeutic options.
It is characterized by severe architectural destruction of the lung
tissue leading to fibrotic changes and resulting in impairment of
gas exchange and finally death due to respiratory failure [1,2]. The
mean survival of patients suffering from IPF is 2–4 years. The
recent research to understand the pathogenesis and progression of
this lethal disease is focused on a dysregulated wound healing
response after repeated injury of the alveolar epithelium [3,4].
Some evidence suggests that injury of the alveolar epithelium may
be a consequence of mechanical stretch caused by alveolar
collapsibility [5,6,7,8,9].
The pathological hallmark of IPF is the pattern of usual
interstitial pneumonia (UIP), characterized by heterogeneously
distributed fibrotic areas and the presence of fibroblastic foci.
Several mechanisms are discussed to contribute to the accumu-
lation of (myo)fibroblasts and the development of fibrosis in the
lung. Some recent evidence suggest the transformation of epithelial
cells into (myo)fibroblasts by a epithelial-mesenchymal transition
(EMT) [10]. There are also reports indicating that fibrocytes
which are of mesenchymal origin are a potential source of
fibroblasts in the fibrotic lungs [11,12]. Moreover, recent data
indicate the presence of a stem cell pool in the lungs [13].
However, the exact origin and functional role of mesenchymal or
resident stem cells with multipotent, self-renewing properties are
not known in detail [14,15].
Several pro- and antifibrotic mediators contribute to the
alveolar repair process in UIP lungs. Among them, hepatocyte
growth factor (HGF) was shown to have anti-fibrotic properties in
an in vivo animal model [16]. HGF induces lung epithelial cell
proliferation, migration and wound repair and exerts anti-
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apoptotic properties in lung epithelial cells, but not in fibroblasts
[17]. HGF was detected in bronchoalveolar lavage (BAL) and
serum of IPF patients [18], however the exact source of HGF in
the fibrotic lung is not known. Recent publications showed
defective HGF production and secretion by fibroblasts obtained
from patients with IPF, indicating that low levels of HGF in the
fibrotic lung may contribute to the development of lung fibrosis.
Similar findings were also reported in bleomycin injured mouse
lungs [19,20,21].
We therefore studied the expression and cellular sources of
HGF in fibrotic lungs of patients suffering from (UIP) and show
that HGF is expressed in specific cells that co-express stem cells
markers. HGF-expressing stem cells stain for CXCR4 and
therefore originate from the bone marrow, exert multipotent,
self-renewing properties in vitro and may have a therapeutic
potential when administered into the fibrotic lung as we
demonstrate in the bleomycin-induced lung injury and fibrosis
model in the rat.
Materials and Methods
Paraffin embedded lung tissue
Lung tissue sections from patients diagnosed with UIP/IPF
(n = 7) according to the ATS/ERS published clinical guidelines
[22,23] were studied. Formalin-fixed and paraffin-embedded lung
wedge resections of patients were obtained from the Institute of
Pathology, University of Bern. Routine hematoxylin and eosin
(H&E), alcianblue as well as elastin-van gieson staining were
performed in all patient samples.
Primary Cell Culture from Human Lung Tissue
Isolation of primary human stem cells was successfully
established using lung tissue obtained from surgical lung biopsies
performed at the Division of Thoracic Surgery, University
Hospital Basel, Switzerland. Primary human stem cells were
isolated from lung tissue biopsies as follows: Peripheral lung tissue
was cut into small pieces of 1 mm3 which were placed into pre-
wetted 25 cm2 cell culture flasks. Culture medium, consisting of
RPMI supplemented with 10% fetal bovine serum (FBS), 20 U/L
penicillin, 20 mg/ml streptomycin and 2.5 mg/ml amphotericin B,
was replaced every fourth day. Cells were grown under standard
conditions (37uC, 21% O2, 5% CO2). For immunofluorescence
staining confluent, non-passaged cells were fixed with 4% formalin
(10 minutes), and permeabilized with methanol/acetic acid (3:1,
ice-cold, 10 minutes).
Human BMSC were obtained from the patients undergoing
orthopedic surgery at the University Hospital Bern, Switzerland.
The cells were grown in Iscove’s Modified Dulbecco’s Media
(IMDM) supplemented with 10%FBS, 1% penicillin/streptomy-
cine (P/S). All experiments were carried out at passage 2–3.
Ethical approval for patient material
[TIGTER]For collection of paraffin embedded lung tissue and
human BMSC, a written informed consent was obtained by the
University Hospital, Bern, following the guidelines and approval
by the Human Ethics Committee of the University of Bern,
Switzerland. Isolation of primary human stem cells using lung
tissue obtained from surgical lung biopsies was approved by the
Human Ethics Committee of the University of Basel, Switzerland.
Written informed consent was obtained from all patients involved
in the study.
Immunohistochemistry
For immunohistochemistry, formalin-fixed human lung tissue
sections were deparaffinized in a xylene series and rehydrated
through a decreasing ethanol series. The slides were pre-treated by
microwave in citrate buffer (100 mM, pH 7.0) for 10 minutes,
washed three times with 1xTBS+0.1% tween and incubated
overnight at 4uC with one of the following antibodies at the
appropriate concentrations against: HGF (1:100) (R&D Systems,
Abingdon, UK), SP-C (1:100) (Santa Cruz CA, USA), c-Met
receptor (1:50) (Calbiochem USA) or Vimentin (1:50) (Sigma
Aldrich USA), CXCR4 (1:500) (Abcam USA), a human mesen-
chymal cell marker panel (CD44 (1:1000), CD45 (1:2000), CD90
(1:500), CD29 (1:500) and CD105 (1:2000) (Abcam USA)), aSMA
(1:100) (Sigma Aldrich, USA), myeloperoxidase (1:500) (Dako
USA), HMB45 (1:50) (Abcam USA) and stained with EnVi-
sionTM+ System-HRP (DAB) (Dako USA). For co-staining, slides
were incubated with different combinations of antibodies: HGF
and SP-C, HGF and aSMA, HGF and CD68, HGF and DC sign,
Figure 1. HGF-positive cells are present in the fibrotic lung. Single mononuclear HGF-positive cells were detected in the broadened alveolar
septum of UIP, many of them in close proximity of alveolar epithelium (a) Furthermore, alveolar epithelial cells stained positive for c-met, the receptor
for HGF (b). magnification (620) inset higher magnification (640).
doi:10.1371/journal.pone.0065453.g001
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HGF and CD44 and HGF and myeloperoxidase,CD29 and
CXCR4; and stained with EnVisionTM DuoFLEX Doublestain
(Dako USA), where DAB was used for HGF and permanent red
for other antibodies (Dako USA). Images were taken using a Leica
DM 3000 microscope.
Immunofluorescence
For immunofluorescence, the slides were pre-treated by
microwave in citrate buffer (100 mM, pH 7.0) for 10 minutes
and then washed with 16PBS before incubation overnight at 4uC
with primary antibodies as described above. After 16 PBS wash
Figure 2. HGF-positive cells do not stain for markers of fibroblasts, dendritic cells, macrophages, myofibroblasts or neutrophils. To
further characterize the HGF-positive cells in UIP, the lung tissues were co-stained with markers of the alveolar epithelium, fibroblasts, myofibroblasts,
dendritic cells and macrophages using specific antibodies. a) Co staining revealed that the HGF-positive cells (green) did not stain for vimentin
(fibroblast marker (red)). (magnification620 (inset higher magnification640), Figure 2a) b) Co staining with SP-C (pink) shows that the HGF signal
(brown) is not present in alveolar epithelial cells (Figure 2b). c) Moreover, no co staining was seen either with CD 68 (macrophage marker) (pink);
(Figure 2c) or with DC sign (dendritic cell marker) (pink)(Figure 2d). (magnification620). Also the co-stainings with alpha smooth muscle actin to
detect myofibroblast (pink) (Figure 2e). (magnification620 (inset 6100), and anti-myeloperoxidase (pink) to detect neutrophils (Figure 2f).
(magnification620 (inset6100), did not show any co staining’s. (In Figure 2b-2f HGF is stained brown) (Arrows indicating positive cells).
doi:10.1371/journal.pone.0065453.g002
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Figure 3. HGF-positive cells stain positive for mesenchymal stromal cell markers. To identify the HGF-positive cells in UIP, the sections
were further stained with the mesenchymal stromal cell markers CD44 and CD105. Cells positive for CD 44 (Figure 3a) were seen in varying numbers
and homogenously distributed in the tissue section. The cells positive for CD 44 (red) co stained for HGF (brown) (Figure 3b) (magnification640).
More information with different markers in the supplement. To further localize these cells in relation to alveolar epithelial cells, the triple
immunofluroscence staining with HGF (green) (Figure 3c), SPc (red) (Figure 3d) and CD 105 (purple) (Figure 3e) was performed. The cells co
expressing CD 105 and HGF, were seen in close proximity to the SP-C positive cells (Figure 3f), (magnification640 oil) for better visualization a 3D
image rendering was done which clearly demonstrates the co expression of CD105 and HGF and also the close proximity of HGF positive
mesenchymal cell to the SPc positive cells (3 g).
doi:10.1371/journal.pone.0065453.g003
Figure 4. HGF positive cells also stain for CXCR4. Triple immunoflurosence was performed to determine if the CXCR4-positive cells have any
correlation with the HGF positive mesenchymal stromal cells, revealed that the cells positive for HGF and CD 105 were also positive for CXCR4. HGF
(green),CD 105 (purple) and CXCR4 (red). (Figure 4a), (magnification660 oil) the right panel is the 3D construction after image rendering for clarity of
the image (Figure 4b), enlarged image for a clear view the colored arrows indicate different staining in the same cell.
doi:10.1371/journal.pone.0065453.g004
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Figure 5. Similar staining pattern was observed in cells isolated from lung biopsies. To further confirm the presence of HGF-secreting
pluripotent stem cells of mesenchymal origin, lung biopsies obtained from patients with UIP were grown in culture and the outgrowing cells were
stained with markers as in the formalin fixed tissues. The isolated cells stained positive for HGF (red) (Figure 5a), similar as seen in the tissue sections.
To further confirm the origin of these isolated cells, co-staining with HGF (red) and CXCR4 (purple) was performed and the similar pattern of
costaining was observed (Figure 5b). Furthermore, a triple immunofluroscence staining with HGF (green), CD105 (purple) and CXCR4 (red) was also
observed (Figure 5c) in the cells derived from lung biopsies of IPF patients. 3D reconstruction for better visualization (Figure 5d). Moreover, HGF
(green) and CXCR4 (red) positive cells also co stained for Oct4 (purple) (Figure 5e), 3D reconstruction for better visualization (Figure 5f)
(magnificationx40 oil).
doi:10.1371/journal.pone.0065453.g005
Figure 6. HGF modified BMSC instilled in the bleomycin induced rat lung were seen in the lung parenchyma. The HGF-positive cells
were distinctly visible in the rat lung parenchyma by immunohistochemistry (brown) (Figure 6a) (magnification 660), triple immunofluroscence
showing BMSC (DiO labeled, green), SP-C (red), HGF (pale yellow) (6b), 3D image for better visualization (6c). (magnification660 oil)
doi:10.1371/journal.pone.0065453.g006
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Figure 7. HGF modified BMSC attenuate bleomycin induced fibrosis in rat lung. To further study the possible therapeutic effect of HGF-
modified BMSC, the cells were administered intratracheally into bleomycin injured lungs of the adult male Fischer (F344) rats. Seven days after
instillation of HGF modified BMSC the lungs were assessed and showed marked improvement in the histological pattern at day 7 (Figure 7c),
compared to control animals (Figure 7a) and the group treated with BMSC only (Figure 7b) furthermore when the animals were sacrificed 14 days
after HGF modified BMSC instillation there was slight improvement (Figure 7f) compared to control (Figure 7d) and BMSC only group (Figure 7e) in
the histological grading which was confirmed with improved Aschroft score (Figure 7h) and reduced collagen content as measured by
hydroxyproline assay (Figure 7 g).
doi:10.1371/journal.pone.0065453.g007
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the slides were treated with the respective secondary antibodies at
a dilution of 1:1000 and incubated in moist chamber for 2 hours at
room temperature. For double staining the procedure was
extended by incubating the slides with the second primary
antibody overnight at 4uC in a moist chamber followed by an
incubation with the corresponding secondary antibody for 2 hour
at room temperature the following day. Double staining was
performed using HGF and Vimentin, CD105, Nanog, Oct3/4,
CD44,CD 90 and CXCR4 respectively. For triple staining, the
slides were incubated with the third primary antibody on the
second day at 4uC overnight in a moist box and the sections were
then treated with the third secondary antibody for 2 hours at room
temperature. The different fluorescent labelled antibodies used
were as CY5 (anti-goat), CY3 (anti-rabbit), FITC (anti-mouse or
anti-rabbit as needed) (Abcam, USA). The various combinations
for triple staining were HGF+SP-C+CD105,
HGF+CD105+CXCR4, HGF+CXCR4+Nanog and
HGF+CXCR4+ Oct3/4.
In vitro alveolar epithelial wound repair assay
Human A549 alveolar epithelial-like cells [American Type
Culture Collection (ATCC), Rockville, MD] and BMSC were
cultured in IMDM supplemented with 10% FBS and 1% P/S.
A549 with Dil (red) and BMSC with DiO (green) were labelled
with Vybrant Multicolor cell labelling kit (Molecular probes,
USA). The cells were labelled with appropriate dye at 37uC for
10 min and then washed twice with 16PBS. After labelling 16105
BMSC were plated on the opposite side of a 4mm pore size high
pore density PET membrane (transwell cell culture insert by
Becton&Dickinson, USA) After 6 hours the transwell inserts were
put in a 24 well plate and 16105 A549 labelled cells were plated
inside the transwell insert; when the A549 cells achieved
confluence, a mechanical wound was created with a pipette tip,
and the co-culture system was placed in serum free media. Images
of the wound surface were captured at time 0 and after 24 hours
using an inverted microscope (Leitz Diavert, Wetzlar, Germany)
connected to a digital camera (Nikon Coolpix). Analysis of the
wound surfaces was performed using Image J software (NIH, USA)
and epithelial wound repair was expressed as percentage of
epithelial wound closure after 24 hours. The co-culture were
washed in PBS and fixed for 15 minutes at room temperature in
3% paraformaldehyde in PBS. Fixed cells were treated with 0.1 M
glycine in PBS and imaged. In in vitro experiments rat BMSC were
used and the similar experiments were repeated using human
BMSC.
Laser Scanning Microscopy and Image Restoration
A Zeiss LSM exciter with an inverted Zeiss microscope
(Axiovert 200M, Lasers: HeNe 633 nm, HeNe 543 nm, and Ar
488 nm) with either a640 or a663 objective lens (oil immersion,
NA = 1.3) was used. Image processing and visualization was
performed using IMARIS (Bitplane AG, Zurich, Switzerland), a
three-dimensional multi-channel image processing software for
confocal microscopic images. For the visualization of three-
dimensional data sets, particularly for the localization of the cells,
with relation to other cells the surpass module from IMARIS was
used, which provides extended functions: the volume rendering,
which displays the volume of the entire data set, or the IsoSurface
visualization, which is a computer-generated representation of a
specific grey value range in the data set. It creates an artificial solid
object to visualize the range of interest of a volume object.
In vivo animal model of bleomycin-induced lung injury
and fibrosis
Animals. Male Fisher F344 rats (240–280 g) were obtained
from Charles River Laboratories GmbH, Sulzfeld Germany.
Experiments were performed in accordance to the standards of the
European Convention of Animal Care. The study protocol was
approved by the University of Bern Animal Study Committee (nr
16/08), using appropriate anesthesia.
Instillation of bleomycin. At day one of the protocol, F344
rats (220–240 g) were anesthetized by inhalation of 4% isoflurane
in a glass chamber, intubated with a 14 GA i.v catheter (Insyte,
Madrid, Spain) and instilled intratracheally with bleomycin (1.28
U/rat) to both lungs. The dosage of bleomycin was based on
preliminary experiments showing induction of pulmonary fibrosis
with lowest mortality.
Isolation and culture of rat bone marrow derived
mesenchymal stem cells
Bone marrow derived mesenchymal stem cells (BMSC) were
isolated from male Fisher F344 rats. The animals were anesthe-
tized by inhalation of 4% isoflurane in a glass chamber, followed
by intraperitoneal administration of Thiopental (50 mg/kg body
weight) to sacrifice the animals. The femur and tibia from the hind
limbs were dissected and skin and muscles were removed. The
isolated femur and tibia were placed in 70% isopropanol for
30 seconds and then transferred in fresh 16PBS. The bones were
cut at the ends and flushed with 1ml 16PBS using a 22G needle,
the follow-through was collected in a sterile tube; each bone was
Figure 8. Increased number of open alveoli and reduced volume of destructed lung parenchyma was observed by unbiased
stereological analysis. Stereological data of total numbers of alveoli per lung (N(alv,lung)) (Figure 8a) and the total volume of destructed lung
parenchyma per lung (V(des,lung)) (Figure 8b). A negative correlation between the number of alveoli and the volume of destructed lung parenchyma
can be established (Figure 8c) p,0.01, r =20.59.
doi:10.1371/journal.pone.0065453.g008
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flushed 2–3 times with a volume of 1ml each time. After
centrifugation the cells were re suspended in IMDM supplemented
with 20% FBS and 1% P/S media and plated in 75 cm flasks and
placed at 37uC at 5% CO2 incubator. After 3 days the medium
was changed, subsequently media was changed every day. For the
experiments the cells were used at passage 2–4.
Flow Cytometry
Cell surface immunophenotype was analyzed by staining the
BMSC with phycoerythrin- or fluorescein isothiocyanate (FITC)-
labeled monoclonal antibodies against CD29, CD90, CD 45,
CD31, CD106 (BD Biosciences), CD44 (Serotec), and antihuman
HGF antibody. The cells were harvested, resuspended in PBS to
obtain a single cell suspension, washed, and incubated for
45 minutes at 4uC in the dark with the staining antibody. For
some experiments, 20 ml FcR blocking reagent per 107 cells were
added (Miltenyi). Unbound antibody was removed by washing the
cells three times in staining buffer (1% BSA and 0.1% NaN3 in
PBS) at 4uC. The cells were then resuspended in staining buffer
and analyzed with the FACScan (Becton Dickinson).
Transfection of Rat BMSC
Rat BMSC were transfected with the plasmid pCikhHGF, human
HGF driven by the human cytomegalovirus (CMV) early promoter
enhancer as described [21] using the Amaxa nucleofection (Lonza,
USA) using U-23 settings following manufacturer’s protocol, 56105
cells were transfected in one cuvette. After transfection the cells were
kept in warm media and either further characterized or instilled
intratracheally in the bleomycin injured animals.
Labelling and instillation of BMSC
BMSC and HGF-modified BMSC were stained with Vybrant
Multicolor cell labelling kit (Molecular probes, USA), following
manufacture’s instructions; briefly, the cells were labelled with
DiO at 37uC for 10 min and then washed twice with 16PBS.
After labelling, the cells were instilled in the rat lung 7 days after
bleomycin instillation. Animals were randomly divided into 4
treatment groups (intratracheal instillation of BMSC or HGF-
modified BMSC, each n = 16) (36106cells/animal) sacrificed at
two different time points (day 7 and day 14 after BMSC
instillation). Six animals from each group at each time points
were subjected to stereological analysis, and ten animals were used
for histology and collagen assays. Additionally two control groups
(intratracheal instillation of media control IMDM, n = 5, or
instillation of fibroblasts n = 5 and were sacrificed at two different
time points (day 7 and day 14 after control media instillation). The
animals were anesthetized as above and intubated with an 14GA
i.v catheter (Insyte, Madrid, Spain). 36106 cells or IMDM control
media were instilled intratracheally in a volume of 500 ml.
Assessment
At day 7 and 14 after BMSC and HGF-modified BMSC
instillation, the animals and control animals were anaesthetized as
described above. Thiopental (50 mg/kg body weight) was admin-
istered intraperitoneally and the animals were ventilated via a
tracheostomy using the Harvard Rodent Ventilator with
FIO2 = 1.0, a frequency of 100 breaths/min, and a tidal volume of
10 ml/kg. Subsequently the pulmonary vessels were flushed with
20 ml of 0.9% saline under pressure of 20 cm H2O. The heart-lung
block was explanted and tissue samples collected for further analysis.
Histology and Ashcroft scoring
Routine haematoxylin and eosin staining was performed with
formalin-fixed tissue sections. In order to evaluate the extent of
pulmonary fibrosis, the scoring system of Ashcroft [24] was used.
Briefly, a score ranging from 0 (normal lung) to 8 (total fibrosis)
was given for each of five randomly chosen microscopic fields and
the mean score of all fields was calculated.
Hydroxyproline Assay
Lungs were analysed for collagen content as initially described by
Woessner [25]. The lungs were excised and snap frozen after having
measured the wet weight. The frozen lungs where homogenized and
1 mL of the homogenate was treated with 10% trichloroactic acid
(TCA), hydrolyzed with 6 M hydrochloric acid (18 hours at 110uC)
and adjusted to pH 7.0. Oxidation was initiated by incubation with
1 ml of chloramin T-reagent for 20 minutes at room temperature
and stopped by addition of 1 ml of 3.15 M perchloric acid. After
incubation with Ehrlich reagent (p-dimethylaminobenzaldehyde
added to methyle cellusolve) for 20 minutes at 55–65uC the
absorbance of each sample was measured at 557 nm. A standard
curve was generated using known concentrations of reagent grade
hydroxyproline (Sigma, USA).
Stereological assessment
Fixation, sampling and processing. For stereological
analysis 6 complete lungs per group were taken at 7 day and 14
day after treatment with transfected or non-transfected BMSC
resulting in 4 groups. The lungs were instillation fixed with a
hydrostatic pressure of 20 cm H2O, using a 4% paraformalde-
hyde/ 0.1% glutaraldehyde mixture in 0.15 M Hepes buffer.
Applying fluid displacement method, the total lung volume
(V(lung)) was determined [26]. To give every part of the lung an
equal chance of being included in the stereological analysis and
thereby representing the whole organ [27] a smooth fractionator
sampling method was applied [28]. Seven to nine tissue blocks per
lung were prepared for light microscopical stereological analysis.
Tissue blocks designated for light microscopy and stereology were
subsequently osmicated, immersed in half-saturated watery uranyl
acetate, dehydrated in acetone and finally embedded in glycol
methacrylate (TechnovitH 8100, Heraeus Kulzer, Wehrheim,
Germany). From each block the 1st and the 4th section of a
consecutive row were cut with a thickness of 1.5 mm, mounted on
a slide and stained with toluidine blue or orceine.
Stereological analysis. At light microscopic level, stereolog-
ical analysis was carried out using an Olympus BC2 light
microscope equipped with a computer-assisted stereology System
(newCAST, Visiopharm, Horsholm, Denmark). All stereological
methods used in this study were based on recently published
guidelines on quantitative assessment of lung structure [29,30].
Assessment was based on a cascade sampling design [31]. By
means of point counting on the toluidine blue stained sections, the
volume fraction of parenchyma within the lung was determined,
defined as regions with maintained parenchymal architecture
likely to contribute to gas exchange (VV(par/lung)). Among the
regions of non-parenchyma, volume fractions of destructed
parenchyma, defined as regions where the normal parenchymal
architecture could not be recognized any more (VV(des/lung))
were further estimated. Destructed lung tissue included above all
fibrotic areas and to a minor amount also inflammatory
infiltrations or alveolar edema. The number of ventilated alveoli
per lung was determined by means of the physical disector using
orceine stained sections [28,32].
As the total lung volume was known, absolute quantities related
to the whole organ could be calculated for each parameter by
HGF Stem Cells Originate from Bone Marrow
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multiplication with the volume fraction according to a cascade
sampling design [30].
Statistical analysis
Data are presented as mean6SEM. Statistical analysis was
performed using non parametric one way ANOVA. Stereological
data between different treatment groups after intervention were
compared using a student`s t-test. Assessment was performed by
means of GraphPad Prism version 4.00 (GraphPad Software, San
Diego, CA). The level of significance was p,0.05.
Results
HGF-positive cells are present in the fibrotic lung
Distinct individual mononuclear cells with positive cytoplasmic
staining for HGF were observed in fibrotic areas of UIP lungs
(Figure 1a), many of them in close proximity of the hyperplastic
alveolar epithelium that stained positive for c-MET receptor, the
receptor for HGF (Figure 1b). Few surfactant protein C (SP-c)
positive cells were observed and were hypertropic (Figure S1). Co-
staining experiments showed that HGF-positive cells did not stain
for vimentin, (Figure 2a, with inset6100) nor surfactant protein C
(SP-C), (Figure 2b), CD-68 (Figure 2c), DC-Sign (Figure 2d), a-
SMA (Figure 2e, with inset6100) or myeloperoxidase (Figure 2f,
with inset6100). These data indicate that HGF-positive cells are
neither alveolar type II epithelial cells nor (myo)fibroblasts nor
macrophages, dendritic cells or neutrophils. HGF was stained
green in immunofluorescence (Figure 2a) and brown in immuno-
histochemistry (Figure 2b–2f).
Stem cells expressing mesenchymal stromal markers are
present in UIP
Cells positive for the mesenchymal markers CD105, CD29,
CD90, CD44 were detected in fibrotic lung tissue obtained from
patients with UIP (Figure 3a; CD44), indicating that mesenchymal
stem cells are present in UIP. We hypothesized that HGF-positive
cells described above may represent a population of mesenchymal
stem cells and performed co-stainings for the above described
mesenchymal stem cell markers. HGF-positive cells in the fibrotic
lung parenchyma stained also positive for CD 105, CD29, CD90,
CD44, indicating that HGF-producing cells in the fibrotic lung are
mainly from mesenchymal origin (Figure 3b; HGF+CD44). We
were not able to detect HGF-positive cells within the area of
fibroblast foci or blood vessels, however, triple immunofluorscence
(HGF+CD105+SP-C-) showed that HGF-positive stem cells are in
close proximity to the alveolar epithelium (Figure 3c-g). These
findings suggest that HGF-positive stem cells may specifically
interact with the injured and hyperplastic alveolar epithelium in
UIP. (Figure S2).
HGF-positive stem cells in UIP originate from the bone
marrow
Stem cells in the lung may be resident lung stem cells as
suggested [13] or mesenchymal stem cells originating from the
bone marrow. To determine the origin of HGF-expressing
mesenchymal stem cells in UIP, immunostaining for CXCR4, a
specific marker for bone marrow derived stem cells, was
performed (Figure S3). Triple immunofluorescence staining for
HGF, the mesenchymal stem cell marker CD105 and CXCR4
indicates that HGF-expressing stem cells in UIP are positive for
CXCR4 and therefore originate from the bone marrow
(Figure 4a–c). Interestingly, all HGF-positive cells detected co-
stained with CXCR4, indicating that HGF-positive cells originate
from the bone marrow (Figure S6).
HGF expressing mesenchymal stem cells in UIP are
pluripotent
To further characterize the HGF-expressing stem cells in UIP,
we studied the expression of two different markers of pluripotency,
OCT3/4 and NANOG. Triple staining with HGF, CXCR4 and
NANOG or Oct 3/4 showed a strong co-staining for all three
markers indicating that HGF-expressing stem cells originating
from the bone marrow are indeed pluripotent (Figure S4).
Isolated human mesenchymal stem cells from UIP lungs
express HGF and are pluripotent
A cell population isolated from surgical lung biopsies from UIP
lungs that was negative for epithelial (surfactant protein A) and
fibroblast (Vimentin) markers stained positive for HGF (5a) and for
the mesenchymal stem cells marker CD105 (Figure 5b). To further
characterize the isolated primary cells from UIP lungs with
mesenchymal stem properties, we stained the cells for HGF and
CXCR4 in vitro (Figure 5c, 5d) and show that the isolated cells
have similar properties as the described HGF-expressing cells in
UIP in vivo, that is are co-staining for HGF and CXCR4
(Figure 5c and 5d). Moreover, the isolated cells also stained
positive for OCT3/4 and NANOG (red) (HGF green, CXCR4
purple) (Figure 5e, 5f), confirming the pluripotency of these cells.
BMSC in the bleomycin lung injury and fibrosis model
To further study the role of HGF-expressing BMSC in the
fibrotic lung, we isolated and cultured BMSC from rats and
instilled them intratracheally in bleomycin-induced fibrotic lungs
after transfection with pCiK-HGF (human hepatocyte growth
factor under control of early CMV promoter enhancer).
Before instillation of BMSC in vivo, we characterized the BMSC
in vitro and show a strong staining for CD90, indicating their
undifferentiated state. BMSC stained positive for other mesen-
chymal markers like CD29, CD44, and CD106, whereas labelling
for CD45 and CD31 (markers for haematopoetic and endothelial
cells) was negative, indicating that BMSC used in passage 2–4
were indeed mesenchymal (Figure S5). After transfection of
BMSC with pCikhHGF, FACS analysis revealed that 71.5% of
the BMSC stained positive for hHGF, indicating a high
transfection rate (Figure S5). After 24 hours in culture, hHGF
levels were 1789064783 ng/ml in conditioned media of trans-
fected cells, indicating that transfected cells secrete biologically
relevant amounts of HGF.
Effects of BMSC and HGF modified BMSC on in vitro
alveolar epithelial wound repair
Wounded A549 monolayer growing in a co-culture system with
BMSC or HGF-modified BMSC were analysed and compared to
wounded A549 monolayer without BMSC as control. Alveolar
epithelial repair in vitro was markedly increased in presence of
BMSC at 24 hours (wound closure 97.73+/23.99% vs 24.14+/
20.82% without BMSC, p = 0.0021). In presence of hHGF
modified BMSC, alveolar epithelial wound closure was further
increased compared to non-transfected BMSC (99.43+/20.42%
(p,0.0001).
BMSC transfected with hHGF attenuate bleomycin
induced lung fibrosis
Based on our in vitro findings on alveolar epithelial wound
repair, we studied HGF-modified BMSC in an in vivo bleomycin
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induced lung injury and fibrosis model. Seven days after
bleomycin injury, BMSC transfected with pCiKHGF were
intracheally instilled (n = 10). Medium alone (n = 5), BMSC
without HGF transfection (n = 10) and fibroblast instilled animals
(n = 5) served as controls. Seven days after BMSC treatment,
distinct HGF positive cells were seen in the rat lung by
immunohistochemistry (Figure 6a), furthermore triple immuno-
fluroscence elucidated that the instilled transfected BMSC
engrafted themselves in the injured lung and also stained positive
for HGF (Figure 6b, 6c). The lung architecture was improved in
the treated group as compared to the control group as shown by
H&E staining (Figure 7a–f). The hydroxyproline content of the
lung treated with BMSC was reduced compared to medium and
fibroblast controls (30666377 mg/mg (BMSC group) vs.
44216469 mg/mg (medium control), p,0.05 and
51006315.5 mg/mg, respectively (fibroblast control)). In animals
treated with HGF-modified BMSC, the hydroxyproline content
was even further reduced to 24466277 ug/mg (p,0.05 compared
to BMSC without HGF modification), indicating that HGF-
modified BMSC reveal even more intensive antifibrotic properties
compared to unmodified BMSC (Figure 7 g). The Ashcroft score
in fibrotic lungs treated with HGF-modified BMSC was lowest
compared to unmodified BMSC or medium control (Figure 7h),
confirming our results obtained with hydroxyproline measure-
ments showing most reduction of bleomycin-induced fibrosis after
treatment with HGF modified BMSC (Ashcroft score 3.0960.2
after HGF-BMSC, 3.8360.1 after BMSC, 5.1260.39 after
medium control treatment and 4.61460.34 in fibroblast treated
group, p,0.05). Moreover, when the animals were sacrificed 14
days after treatment the values of hydroxyproline were further
reduced in the BMSC group at day 14 (1327651.18 ug/mg vs
12658561082 ug/mg in the medium control group), however
there was no difference in the collagen content between BMSC
alone and HGF modified BMSC (14876110.1 ug/mg). The
Ashcroft score in the HGF-BMSC group, however, showed a
significant improvement compared to the BMSC group at day 14
(2.71460.21 vs 3.70960.25, p,0.05).
Stereological data assessed from fibrotic lungs treated
with HGF-expressing BMSC
Stereological data (individual data and mean) are illustrated in
Figure 8. The number of ventilated (open) alveoli was higher in
animals after treatment with HGF-transfected BMSC compared
to treatment with non-transfected BMSC. (Figure 8a). The total
volume of destructed lung tissue on the other hand was slightly,
but not significantly reduced in the HGF transfected BMSC
groups compared to BMSC groups at both time points (Figure 8b).
Regardless whether BMSC were transfected with HGF or not, a
decrease of the total volume of destructed lung tissue was
observed. A significant negative correlation between the number
of open alveoli and the total volume of destructed lung tissue
volume was demonstrated (Figure 8c, r =20.59, p,0.01). The
lower the volume of destructed lung tissue, the higher the number
of ventilated alveoli. Taken together, these data are in line with the
Ashcroft score indicating that transfection of BMSC with the
human HGF-gene enhances the antifibrotic properties and the
potential to restore the normal lung architecture.
Discussion
In this study we show that pluripotent mesenchymal stem cells
originating from the bone marrow are present in UIP lungs and
express HGF. HGF-modified BMSC reduce pulmonary fibrosis in
the bleomycin induced lung injury and fibrosis model, indicating
that HGF-transfected BMSC have enhanced regenerative prop-
erties and an increased potential to restore normal lung
architecture as clearly demonstrated by Ashcroft score and the
increased number of open alveoli. We therefore conclude that
HGF-positive stem cells detected in UIP may rather be antifibrotic
and therefore HGF-modified BMSC might represent a novel
therapeutic strategy in patients with UIP/IPF in the future.
HGF is a pleiotropic growth factor having mitogenic activities
on alveolar epithelial cells [33], contributes to the morphogenesis
of the developing lung epithelium [34], has anti-apoptotic
properties on the lung epithelium and induces apoptosis of
(myo)fibroblasts [35]. Few studies including our own [16,36]
proved that HGF induces alveolar epithelial wound repair in vitro
and attenuates bleomycin induced lung injury and fibrosis in vivo.
In patients with IPF, Marchand-Adam S et al showed defective
HGF secretion from fibroblasts obtained from UIP lungs [37]. In
this respect, HGF may present the basis of a promising novel
strategy for the treatment of pulmonary fibrosis.
However, in UIP it is not clear if and by which cells HGF is
expressed. In vitro studies showed that in specific conditions various
cell types like fibroblasts [38], alveolar epithelial cells [18],
macrophages [39], dendritic cells [40], neutrophils [41,42,43], or
myofibroblasts [44] can be a source of HGF. In our study we
clearly identified specific HGF-positive cells in the fibrotic lung
parenchyma of UIP that co-stained with CD29, CD44, CD90,
CD105, and CXCR4, confirming that HGF expressing cells are
mesenchymal stem cells that originate from the bone marrow.
Over recent years mesenchymal stromal cells (also referred to as
stem cells) have gained a lot of attention due to their possible
therapeutic potential, which has been demonstrated in various
rodent disease models [45]. Stem cells in the lung may either
originate from the bone marrow, being recruited to the lung in
case of lung injury, or represent endogenous stem cells. Recent
studies reported the presence of multipotent, endogenous or lung-
resident stem cells in adult human lungs [46]. In contrast to our
findings, Lama VN et al [46] suggested that lung resident
mesenchymal stem cells are endogenous and do not originate
from the bone marrow. This data is based on the study of sex
chromosome status in the sex mismatched organ transplant
recipient. However, the value of the study was limited by the
small number of BAL cells studied which may differ from stem
cells within the lung parenchyma. In line with our data, Kajstura J
et al [13] showed that stem cells are present in the human lung,
however they did not discuss the origin of these cells neither
compared them to pathological lung conditions such as UIP. In
our study we analyzed HGF-expressing stem cells in the fibrotic
lung parenchyma of UIP that showed positive staining for
CXCR4, clearly indicating that they are bone marrow derived
since CXCR4 positivity was shown to represent a reliable marker
of bone marrow origin [47]. These findings are in agreement to
further reports showing that bone marrow stromal cells actively
migrate to the site of injury [48,49,50,51], a process that is
mediated in part by the CXCR4 – SDF axis [52]. Since HGF-
expressing, CXCR4+ cells in UIP did neither co-stain with
vimentin nor with a-SMA, we assume that these cells are not
fibrocytes that were recently described to play a major role in the
pathogenesis of pulmonary fibrosis [53].
In our study HGF+ cells in UIP also expressed Oct3/4 and
NANOG, two transcription factors characteristic of pluripotent
stem cells. Interestingly, isolated cells from surgical lung biopsies
obtained from patients with UIP/IPF were also positive for
mesenchymal stem cell markers, expressed HGF and expressed
markers of pluripotency (Oct3/4, NANOG), in a similar pattern as
observed in paraffin embedded tissue sections.
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In order to characterize the role of HGF-expressing stem cells
originating from the bone marrow, we performed in vitro and in vivo
studies using BMSC obtained from humans and rats. We
transfected BMSC with human HGF (hHGF) and studied the
effect of HGF-modified BMSC in an in vitro alveolar epithelial
wound repair model using human lung epithelial cells. Finally we
instilled HGF-modified rat BMSC intratracheally in bleomycin
injured rat lungs. These HGF-expressing BMSC increased
alveolar epithelial wound repair in vitro compared to unmodified
BMSC. Moreover, HGF-expressing BMSC significantly reduced
bleomycin induced lung fibrosis as shown by hydroxyproline assay,
Ashcroft score and stereological data analysis. The repairing and
antifibrotic effect of HGF-expressing BMSC was considerably
higher compared to unmodified BMSC (or medium control) at day
7 post treatment. However, there was no difference in the total
collagen content 14 days after BMSC or HGF expressing BMSC
treatment.
To further assess the effects of HGF-expressing BMSC or
unmodified BMSC on lung structure, stereological analysis was
performed. Both types of cells were associated with the attenuation
of pathological alterations with time as indicated by a decline of
the volume of destructed lung tissue and an increase in the number
of ventilated alveoli. In addition, differences regarding the
efficiency to attenuate pathological alterations could be found.
The total volume of destructed lung parenchyma was decreased by
trend in HGF-modified BMSC as compared to unmodified BMSC
both one and two weeks after instillation of these cells. Moreover,
the number of ventilated alveoli was significantly higher in lungs
treated with HGF-modified BMSC. In contrast to our data a
previous study found 10.5 million alveoli in the normal right lung
of Fischer 344 rats of similar age [54] indicating that neither HGF-
expressing BMSC nor unmodified BMSC were able to completely
restore normal lung architecture two weeks after treatment.
Alveolar collapse and collapse induration have been reported to be
involved in pathogenesis of fibrosing lung diseases [7,8,55]. The
negative correlation between the number of ventilated alveoli and
the total volume of destructed lung parenchyma suggests that in
particular HGF-expressing BMSC lead to a re-opening of
previously collapsed alveoli [5,6]. At the ultrastructural level,
collapsed alveoli with opposing denuded basal laminae are a
common pathology in the bleomycin-model of the rat lung 7 to 14
days after bleomycin-instillation [56]. Suggesting enhanced repair
of the alveolar epithelium in this period occurs and might facilitate
the re-opening of collapsed alveoli. Bleomycin injury model does
not exactly represent the UIP in terms of the onset and progress of
fibrosis; however it is the most commonly used model and partly
represents the architectural destruction of the lung, and we show a
significant repair reduction of fibrosis in the model using HGF-
expressing BMSC.
This potential mechanism is supported by in vitro co culture data
where regeneration of a wounded A549 epithelial monolayer was
efficiently achieved by BMSC after HGF-gene transfection. Thus,
the increased number of alveoli in the lungs having received HGF-
transfected BMSC is in line with the notion that HGF enhances
regeneration of the alveolar epithelial lining in vivo [57]. Our
previous study did not show any evidence of neo-alveolarisation in
healthy lungs overexpressing human HGF specifically by alveolar
type II cells [54]. However, the number of alveoli per lung is not a
static parameter and in the rat lung late alveolarisation has been
discussed, meaning that alveolar number may increase after
maturity [58]. Thus, faced with higher levels of HGF, neo-
alveolarisation might contribute to an increase of the alveolar
number reported here.
In conclusion we report the presence of pluripotent, HGF-
expressing stem cells in UIP lungs that originate from the bone
marrow. Transfection of rat BMSC with the human HGF gene
markedly enhanced their potential to restore normal lung tissue
structure after bleomycin lung injury and fibrosis, possibly by
reopening the previously collapsed alveoli. Our data indicate that
both pluripotent stem cells and HGF may have a beneficial effect
in lung fibrosis and may represent the basis of a novel therapeutic
approach for patients suffering from UIP/IPF.
Supporting Information
Figure S1 The lung sections were stained for surfactant
protein C (SP-c), the marker for alveolar epithelial type
II cells, not too many positive cells were observed,
moreover the observed positive cells where hypertro-
phic.
(TIF)
Figure S2 Cells positive for CD 105 (a), CD 29 (b), CD 90
(c), were seen in varying numbers and were distributed
at various locations in the tissue section. Furthermore, the
sections were co stained with. Immunofluroscence with CD 105
and HGF also showed the same results (HGF green (d), CD 105
red (e), merged image (f).
(TIF)
Figure S3 To identify the origin of HGF secreting,
mesenchymal stromal cells, the tissue sections were
stained with CXCR4. Cells positive for CXCR4 were present
in the lung parenchyma.
(TIF)
Figure S4 To ascertain if meschenchymal stromal cells
of bone marrow origin expressing HGF have pluripotent
properties, sections were stained for markers of pluri-
potency, a triple staining was performed which exhib-
ited that HGF (green) and CXCR4 (red) positive cells
were also immunoreactive to Nanog (Purple) (a). For clear
visualization, 3D image is shown (b).
(TIF)
Figure S5 The BMSC isolated from the rat where
characterized with the known mesenchymal markers
(a), significantly higher number of rat BMSC were
successfully transfected with human HGF (b).
(TIF)
Figure S6 To further confirm that the cells present in
the lung are originating from the bone marrow, a
costaining with various mesenchymal markers and
CXCR4 was performed. A double immunofluroscence
CXCR4 (green) and CD 44 (purple) (a), CXCR4 (green) and
CD 90 (purple) (b) CXCR4 (brown) and CD 29 (pink) (c),
costaining of CXCR 4 with other mesenchymal markers confirm
our findings.
(TIF)
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